New England Capital Financial Advisors LLC Sells 773 Shares of Kenvue Inc. (NYSE:KVUE)

New England Capital Financial Advisors LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 22.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,614 shares of the company’s stock after selling 773 shares during the period. New England Capital Financial Advisors LLC’s holdings in Kenvue were worth $56,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC bought a new position in shares of Kenvue during the 4th quarter valued at $140,000. Parkside Financial Bank & Trust lifted its holdings in shares of Kenvue by 20.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 18,258 shares of the company’s stock valued at $393,000 after buying an additional 3,057 shares during the period. Illinois Municipal Retirement Fund lifted its holdings in shares of Kenvue by 704.8% during the 4th quarter. Illinois Municipal Retirement Fund now owns 301,913 shares of the company’s stock valued at $6,500,000 after buying an additional 264,397 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Kenvue by 4.1% during the 4th quarter. New York State Common Retirement Fund now owns 2,368,935 shares of the company’s stock valued at $51,003,000 after buying an additional 94,284 shares during the period. Finally, PDS Planning Inc bought a new position in shares of Kenvue during the 4th quarter valued at $265,000. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

KVUE stock traded down $0.22 during trading on Tuesday, reaching $19.36. The company’s stock had a trading volume of 19,764,634 shares, compared to its average volume of 16,661,875. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The company’s fifty day moving average is $19.84 and its 200-day moving average is $20.16.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s revenue was down 2.7% on a year-over-year basis. Analysts predict that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.13%.

Wall Street Analyst Weigh In

KVUE has been the topic of several research analyst reports. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. The Goldman Sachs Group initiated coverage on Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. Finally, William Blair initiated coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.